Skip to main content
Turkish Journal of Hematology logoLink to Turkish Journal of Hematology
. 2015 May 8;32(2):193–194. doi: 10.4274/tjh.2014.0211

Promyelocytic Blastic Crisis in Chronic Myeloid Leukemia During Imatinib Treatment

İmatinib Tedavisi Sırasında Kronik Miyeloid Lösemide Gelişen Promiyelositik Blastik Kriz

Federico Angriman 1,*, Maria Nelly Gutierrez Acevedo 2, Maria Sol Rossi 2, Alberto Daniel Gimenez Conca 3, Victoria Otero 3, Jorge Alberto Arbelbide 3, Hernán Michelángelo 2
PMCID: PMC4451494  PMID: 26316496

An 82-year-old woman was admitted to our hospital presenting with febrile neutropenia. She had been diagnosed with chronic myeloid leukemia 2 years ago and had been on imatinib treatment since [1]. A month before admission she presented with malaise, anemia, and mild leukopenia; a bone marrow aspirate and biopsy performed 20 days before admission showed no alterations. Imatinib dosing was adjusted but mild cytopenia persisted. The patient presented with acute abdominal pain, fever, and shaking chills to the emergency department. On physical examination the patient was awake and appeared uncomfortable. She had pain in the left lower abdominal quadrant. Petechiae were evident on the lower limbs. Complete blood count revealed anemia, severe neutropenia, and thrombocytopenia (Table 1). Overt disseminated intravascular coagulation was present. Abdominal computed tomography showed acute diverticulitis. The patient was started on broad-spectrum antibiotics. Informed consent was obtained.

Table 1. Results of laboratory testing.

graphic file with name TJH-32-193-g1.jpg

A peripheral blood smear revealed more than 30% circulating promyelocytic blasts. A bone marrow aspirate and biopsy showed hypercellular marrow with myeloid hyperplasia and more than 90% myeloblasts (Figure 1). The blasts displayed hypergranular cytoplasm with bundles of Auer rods. PML/RAR-α was positive according to real-time PCR of the bone marrow. A diagnosis of promyelocytic blastic crisis was made [2,3,4,5].

Figure 1. Leukemic cell morphology of bone marrow aspiration specimen (May-Grünwald-Giemsa).

Figure 1

Footnotes

Conflict of Interest Statement

The author of this paper has no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

References

  • 1.Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164–172. doi: 10.1056/NEJM199907153410306. [DOI] [PubMed] [Google Scholar]
  • 2.Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004;103:4010–4022. doi: 10.1182/blood-2003-12-4111. [DOI] [PubMed] [Google Scholar]
  • 3.Shichishima T, Abe R, Satoh T, Kawaguchi M, Uchida T, Kariyone S. Promyelocytic crisis of chronic myelocytic leukemia: case report and review of the literature. Nihon Ketsueki Gakkai Zasshi. 1987;50:1190–1195. [PubMed] [Google Scholar]
  • 4.Abe R, Shichishima T, Kawaguchi M, Uchida T, Kariyone S. Promyelocytic crisis of chronic myelogenous leukemia without t(15;17) Cancer Genet Cytogenet. 1986;21:175–179. doi: 10.1016/0165-4608(86)90044-0. [DOI] [PubMed] [Google Scholar]
  • 5.Gozzetti A, Bocchia M, Calabrese S, Pirrotta MT, Crupi R, Raspadori D, Lauria F. Promyelocytic blast crisis of chronic myelogenous leukemia during imatinib treatment. Acta Haematol. 2007;117:236–237. doi: 10.1159/000099548. [DOI] [PubMed] [Google Scholar]

Articles from Turkish Journal of Hematology are provided here courtesy of Galenos Yayinevi

RESOURCES